Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) have earned a consensus rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $54.25.

A number of research firms have recently weighed in on TNDM. Wells Fargo & Company raised their price target on shares of Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. UBS Group upgraded Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Sanford C. Bernstein started coverage on Tandem Diabetes Care in a research note on Wednesday, November 6th. They set an “outperform” rating and a $42.00 price target for the company. Barclays increased their price objective on Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a report on Friday. Finally, Morgan Stanley restated an “equal weight” rating and issued a $45.00 target price on shares of Tandem Diabetes Care in a report on Monday, September 23rd.

Tandem Diabetes Care Price Performance

TNDM opened at $31.37 on Tuesday. The stock has a fifty day moving average price of $38.73 and a 200 day moving average price of $41.91. The company has a current ratio of 2.90, a quick ratio of 2.38 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care has a 1 year low of $14.33 and a 1 year high of $53.69. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -16.25 and a beta of 1.36.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $243.97 million during the quarter, compared to analyst estimates of $224.14 million. During the same period in the previous year, the company earned ($0.38) EPS. The firm’s revenue was up 31.4% on a year-over-year basis. Analysts forecast that Tandem Diabetes Care will post -1.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Assetmark Inc. acquired a new stake in Tandem Diabetes Care during the third quarter worth $29,000. ORG Wealth Partners LLC acquired a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at about $30,000. ORG Partners LLC bought a new stake in Tandem Diabetes Care in the second quarter valued at about $31,000. Headlands Technologies LLC bought a new stake in Tandem Diabetes Care in the first quarter valued at about $35,000. Finally, Waldron Private Wealth LLC acquired a new position in Tandem Diabetes Care in the third quarter worth about $50,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.